Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis

BACKGROUND: Atezolizumab plus chemotherapy has been recommended as a first-line treatment option for patients with advanced non-small cell lung carcinoma (NSCLC) irrespective of programmed cell death-ligand 1 (PD-L1) expression. Currently, little is known about the efficacy and treatment-related adv...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Autores principales: Li, Dan-Ni, Lu, Wen-Qing, Yang, Bo-Wen, Zhang, Ling-Yun, Jin, Bo, Wang, Shuo, Che, Xiao-Fang, Li, Ce, Liu, Yun-Peng, Qu, Xiu-Juan
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212861/
https://ncbi.nlm.nih.gov/pubmed/34149702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.666909
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares